title: Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa.
abstract: In 31 adult patients with cystic fibrosis (CF) who were chronically infected with Pseudomonas aeruginosa we examined the effect of giving regular three monthly oral ciprofloxacin. Patients received ciprofloxacin or placebo for 10 days every 3 months for 1 yr in a randomized, double-blind, placebo-controlled study. During each course of treatment patients receiving ciprofloxacin reported an improvement in cough, sputum production and peak expiratory flow (PEF) P = < 0.005. During the year of study patients receiving ciprofloxacin showed an improvement in PEF when compared with those receiving placebo (P = < 0.05) but the changes in FEV1 and FVC were not statistically different in either group. Regular oral ciprofloxacin was well tolerated but did not prevent hospital admissions or reduce the number of courses of intravenous antibiotics throughout the year. The median MIC to ciprofloxacin in the active treatment group rose from 0.5 mg l-1 to 0.75 mg l-1 during treatment. We conclude that CF patients are likely to benefit from oral ciprofloxacin for exacerbations of respiratory symptoms. However, regular treatment with ciprofloxacin over 1 yr improves PEF but does not reduce the rate of hospital admissions with acute exacerbations of respiratory symptoms.
authors.affiliation: Department of Cystic Fibrosis, Royal Brompton National Heart & Lung Hospitals, Chelsea, London, U.K.
authors.forename: C D
authors.initials: CD
authors.lastname: Sheldon
authors.forename: B K
authors.initials: BK
authors.lastname: Assoufi
authors.forename: M E
authors.initials: ME
authors.lastname: Hodson
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002908:Chronic Disease; D002939:Ciprofloxacin / Q000008:administration & dosage*; D003550:Cystic Fibrosis / Q000150:complications*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D009894:Opportunistic Infections / Q000150:complications*; D011552:Pseudomonas Infections / Q000188:drug therapy*
chemical_list: D002939:Ciprofloxacin